Joincare Pharmaceutical Group Industry (600380.SH) has obtained the Drug Clinical Trial Approval Notification.
Jiankangyuan (600380.SH) announced that the company has recently received the "Clinical Trial Approval Notice for Drugs" approved and issued by the National Medical Products Administration, allowing the company to carry out clinical trials for the new -lactamase inhibitor applied.
Joincare Pharmaceutical Group Industry (600380.SH) announced that recently, the company has received the "Notice of Approval for Clinical Trial of Drugs" issued by the National Medical Products Administration, approving the company's application for clinical trials of a new type of -lactamase inhibitor.
In accordance with the "Drug Administration Law of the People's Republic of China" and related regulations, after review, the clinical trial application for injection of JKN2501 submitted on February 12, 2026 meets the relevant requirements for drug registration, and it is approved for conducting clinical trials for use in combination with Meropenem, for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia caused by gram-negative or gram-positive bacteria.
Related Articles
10 billion yuan corporate bonds issued by Tianneng Battery Group Co., Ltd. have been completed.
Chengdu Easton Biopharmaceuticals (688513.SH): Two types of improved new drugs, acetaminophen hydroxypropanone sustained-release tablets, have obtained drug registration certificates.
Muyuan Foods (02714) generated around 8.503 billion yuan in revenue from pig sales in April, a year-on-year decrease of 32.49%.
10 billion yuan corporate bonds issued by Tianneng Battery Group Co., Ltd. have been completed.
Chengdu Easton Biopharmaceuticals (688513.SH): Two types of improved new drugs, acetaminophen hydroxypropanone sustained-release tablets, have obtained drug registration certificates.
Muyuan Foods (02714) generated around 8.503 billion yuan in revenue from pig sales in April, a year-on-year decrease of 32.49%.
